EyePoint Pharmaceuticals (EYPT) News Today

Swiss National Bank acquired a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 86,700 shares of the company's stock, valued at approximately $1,792,000. Swiss Nation

Lord Abbett & CO. LLC lessened its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 34.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 242,580 sh

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) Director David R. Guyer sold 11,625 shares of the business's stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $10.06, for a total value of $116,947.50. Following the transaction, the director now directly owns 1,850 shares in the company, valued at approximately $18,611. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3.4%

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 12.2%

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 8,980,000 shares, a growth of 16.0% from the May 31st total of 7,740,000 shares. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 8.2 days.

Chardan Capital reissued a "buy" rating and set a $28.00 target price on shares of EyePoint Pharmaceuticals in a report on Friday.

HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year target price among analysts th

Cantor Fitzgerald reissued an "overweight" rating on shares of EyePoint Pharmaceuticals in a research report on Thursday.

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 137,000 shar

Ghisallo Capital Management LLC purchased a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 108,634 shares of the company's sto

Sectoral Asset Management Inc. decreased its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 53.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,160 shares of the company's stock after

Scotia Capital Inc. lowered its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 90.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 8,963 shares of the company's stock after selling 82,000 shares during the p

JPMorgan Chase & Co. reduced their price objective on shares of EyePoint Pharmaceuticals from $35.00 to $32.00 and set an "overweight" rating for the company in a research report on Tuesday.

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 6.4%

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price tar

Monashee Investment Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 175,000 shares of the company's stock, va

Franklin Resources Inc. boosted its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 11.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,640,651 shares of the com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 3.8% on Insider Selling

EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.5%

First Turn Management LLC acquired a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 317,010 shares of the company's stock, valued at appro

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research report issued on Monday, May 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for EyePoint Pharmaceuticals in a note issued to investors on Monday, May 13th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.49) per share for t

HC Wainwright cut their target price on shares of EyePoint Pharmaceuticals from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 850,000 shares of the stock in a transaction dated Monday, May 6th. The shares were bought at an average cost of $11.86 per share, for a total transaction of $10,081,000.00. Following the acquisition, the insider now owns 8,325,000 shares in the company, valued at approximately $98,734,500. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Robert W. Baird cut their price target on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an "outperform" rating for the company in a report on Wednesday.

Chardan Capital decreased their target price on EyePoint Pharmaceuticals from $39.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday.